ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ¿ëµµº°, Á¦Ç°º°, ±â¼úº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Human Papilloma Virus Testing Market Size, Share & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå
:
1813883
¸®¼Ä¡»ç
:
Grand View Research
¹ßÇàÀÏ
:
2025³â 08¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 110 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ¿ä¾à
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð´Â 2024³â 17¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2033³â¿¡´Â 56¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2033³â±îÁö CAGR 14.14%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀåÀº ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV)°¡ ÀڱðæºÎ¾ÏÀÇ 95% ÀÌ»óÀ» À¯¹ßÇÏ´Â HPV °ü·Ã ¾ÏÀÇ Áõ°¡·Î ÀÎÇØ Ȱ¼ºÈµÇ°í ÀÖ½À´Ï´Ù.
È£ÁÖ¿Í °°Àº ±¹°¡¿¡¼´Â ´õ ³ôÀº ¹Î°¨µµ¸¦ À§ÇØ ÀڱðæºÎ¾Ï °Ë»ç¸¦ HPV DNA °Ë»ç·Î ´ëüÇϰí ÀÖ½À´Ï´Ù. BD³ª Ȧ·ÎÁ÷°ú °°Àº ¼¿ÇÁ »ùÇøµ ŰƮ´Â ¼ºñ½º°¡ ÃæºÐÈ÷ Á¦°øµÇÁö ¾Ê´Â Áö¿ª¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¾ÆÇÁ¸®Ä«¿Í ¾Æ½Ã¾Æ¿¡¼´Â WHOÀÇ ÅðÄ¡ Àü·«°ú NGO°¡ Áö¿øÇÏ´Â ÇÁ·Î±×·¥ÀÌ º¸±ÞÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÐÀÚÁø´ÜÀÇ ¹ßÀü, ¹øµéÇü ¿©¼º °Ç° ÆÐ³Î, ½ÇÇè½Ç ÀÎÇÁ¶óÀÇ °³¼±À¸·Î Àü ¼¼°èÀûÀ¸·Î °Ë»ç Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ºñ¿ë È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ÀڱðæºÎ¾ÏÀº Àü ¼¼°è ¿©¼º¿¡°Ô 4¹øÂ°·Î ÈçÇÑ ¾ÏÀ̸ç, ¿©¼º ¾Ï °ü·Ã »ç¸Á ¿øÀÎ Áß 2À§¸¦ Â÷ÁöÇÕ´Ï´Ù.
2020³â 11¿ù, ¼¼°èº¸°Ç±â±¸(WHO)´Â 'ÀڱðæºÎ¾Ï ÅðÄ¡¸¦ À§ÇÑ ¼¼°è Àü·«'À» ¹ßÇ¥Çϰí, 2030³â±îÁö '90-70-90' ¸ñÇ¥¸¦ ¼³Á¤Çß´Ù - 15¼¼±îÁö ¿©¾Æ 90%¿¡°Ô ¹é½ÅÀ» Á¢Á¾Çϰí, 35¼¼¿Í 45¼¼ ¿©¼ºÀÇ 70%¸¦ °ËÁøÇϰí, Áúº´ÀÌ È®ÀÎµÈ ¿©¼ºÀÇ 90%¸¦ Ä¡·áÇÕ´Ï´Ù. Ä¡·áÇÕ´Ï´Ù. 2022³â, ±ÇÀå °ËÁø ¼ö°Ë·ü 70% ÀÌ»ó¿¡ µµ´ÞÇÑ ±¹°¡´Â 18%¿¡ ºÒ°úÇϸç, Àü ¼¼°è ¼ö°Ë·üÀº ¾ÆÁ÷ ¾à 20%¿¡ ºÒ°úÇÕ´Ï´Ù. HPV´Â ÀڱðæºÎ¾Ï ȯÀÚÀÇ 99.8%ÀÇ ¿øÀÎÀ̸ç, À¯ÀüÀÚÇü 16°ú 18Çü¸¸ 70%¸¦ Â÷ÁöÇÕ´Ï´Ù. 19°¡Áö °íÀ§Çè À¯ÀüÀÚÇüÀÌ HPV °ü·Ã ¾ÏÀÇ 90%¸¦ Â÷ÁöÇÕ´Ï´Ù. HPV °¨¿°Àº ´ëºÎºÐ ¹«Áõ»óÀ̱⠶§¹®¿¡ Á¶±â ¹ß°ßÀ» À§Çؼ´Â ºÐÀÚ °Ë»ç°¡ ÇʼöÀûÀÔ´Ï´Ù. 2017³â ÀÌÈÄ È£ÁÖ, ³×´ú¶õµå µîÀÇ ±¹°¡¿¡¼´Â ¹Î°¨µµ°¡ ³ô°í °ËÁø °£°ÝÀÌ ±æ´Ù´Â ÀÌÀ¯·Î ÀڱðæºÎ¾Ï °Ë»ç¿¡¼ 1Â÷ HPV DNA °Ë»ç·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óºÎ ½ÃÀå Àü¸Á
°ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ºÐ¼® Åø
¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
PESTLE ºÐ¼®
Á¦4Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
¿ëµµ ºÎ¹® ´ë½Ãº¸µå
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¿ëµµº°, 2021-2033³â
ÀڱðæºÎ¾Ï °ËÁø
Áú¾Ï °ËÁø
Á¦5Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
Á¦Ç° ºÎ¹® ´ë½Ãº¸µå
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Á¦Ç°º°, 2021-2033³â
±â±â
¼Ò¸ðǰ
¼ºñ½º
Á¦6Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®
±â¼ú ºÎ¹® ´ë½Ãº¸µå
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ±â¼úº°, 2021-2033³â
PCR
¸é¿ªÁø´Ü
±âŸ
Á¦7Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
ÃÖÁ¾ ¿ëµµ ºÎ¹® ´ë½Ãº¸µå
ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
¼¼°èÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2021-2033³â
º´¿ø°ú Áø·á¼Ò
¿¬±¸¼Ò
±âŸ
Á¦8Àå ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
Áö¿ª ½ÃÀå ´ë½Ãº¸µå
Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2021³â ¹× 2033³â
Áö¿ªº° ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV) °Ë»ç ½ÃÀå : ÁÖ¿ä Æ÷ÀÎÆ®
ºÏ¹Ì
À¯·´
µ¶ÀÏ
¿µ±¹
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
½º¿þµ§
³ë¸£¿þÀÌ
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
Çѱ¹
È£ÁÖ
ű¹
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
±â¾÷/°æÀï ºÐ·ù
º¥´õ »óȲ
Key Company Heat Map Analysis, 2024
±â¾÷ °³¿ä
Abbott
Biomedical Diagnostics
bioMerieux
Bio-Rad Laboratories, Inc.
Fujirebio
Oncolab
Hologic, Inc.
Qiagen
F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
KSM
¿µ¹® ¸ñÂ÷
Human Papilloma Virus Testing Market Summary
The human papilloma virus testing market size was estimated at USD 1.76 billion in 2024 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 14.14% from 2025 to 2033. The market is fueled by rising HPV-related cancer cases, with human papilloma virus (HPV) causing over 95% of cervical cancers.
Countries like Australia have replaced Pap smears with HPV DNA testing for higher sensitivity. Self-sampling kits, such as those from BD and Hologic, are expanding access in underserved areas. WHO's elimination strategy and NGO-backed programs in Africa and Asia drive adoption. Advances in molecular diagnostics, bundled women's health panels, and improved lab infrastructure make testing more accessible and cost-effective globally. Cervical cancer is the fourth most common cancer among women worldwide and the second leading cause of female cancer-related mortality.
In November 2020, the World Health Organization launched its Global Strategy to Eliminate Cervical Cancer, setting the 90-70-90 targets for 2030-vaccinate 90% of girls by age 15, screen 70% of women at ages 35 and 45, and treat 90% of women with identified disease. This initiative came against alarming statistics: in 2022, only 18% of countries had reached the recommended screening coverage of over 70%, and global coverage still stood at about 20%. HPV is the causative agent in 99.8% of cervical cancer cases, with genotypes 16 and 18 alone responsible for 70% of cases. Nineteen high-risk genotypes account for 90% of all HPV-related cancers. Given the asymptomatic nature of most HPV infections, molecular testing has become essential for early detection. Since 2017, countries such as Australia and the Netherlands have transitioned from Pap smears to primary HPV DNA testing, citing higher sensitivity and longer screening intervals.
Global Human Papilloma Virus Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report based on application, product, technology, end use, and region:
Application Outlook (Revenue, USD Million, 2021 - 2033)
Cervical Cancer Screening
Vaginal Cancer Screening
Product Outlook (Revenue, USD Million, 2021 - 2033)
Instruments
Consumables
Services
Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR
Immunodiagnostics
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals & Clinics
Laboratories
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Product
1.2.3. Technology
1.2.4. End Use
1.2.5. Regional Scope
1.2.6. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application Outlook
2.2.2. Product Outlook
2.2.3. Technology Outlook
2.2.4. End Use Outlook
2.2.5. Regional Outlook
2.3. Competitive Scenario
Chapter 3. Human Papilloma Virus (HPV) Testing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Human Papilloma Virus (HPV) Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Human Papilloma Virus (HPV) Testing Market: Application Estimates & Trend Analysis
4.1. Application Segment Dashboard
4.2. Human Papilloma Virus (HPV) Testing Market: Application Movement Analysis
4.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Application, 2021 - 2033 (USD Million)
4.4. Cervical Cancer Screening
4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Vaginal Cancer Screening
4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Human Papilloma Virus (HPV) Testing Market: Product Estimates & Trend Analysis
5.1. Product Segment Dashboard
5.2. Human Papilloma Virus (HPV) Testing Market: Product Movement Analysis
5.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Product, 2021 - 2033 (USD Million)
5.4. Instruments
5.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Consumables
5.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Services
5.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Human Papilloma Virus (HPV) Testing Market: Technology Estimates & Trend Analysis
6.1. Technology Segment Dashboard
6.2. Human Papilloma Virus (HPV) Testing Market: Technology Movement Analysis
6.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By Technology, 2021 - 2033 (USD Million)
6.4. PCR
6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Immunodiagnostics
6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Human Papilloma Virus (HPV) Testing Market: End Use Estimates & Trend Analysis
7.1. End Use Segment Dashboard
7.2. Human Papilloma Virus (HPV) Testing Market: End Use Movement Analysis
7.3. Global Human Papilloma Virus (HPV) Testing Market Size & Trend Analysis, By End Use, 2021 - 2033 (USD Million)
7.4. Hospitals & Clinics
7.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Laboratories
7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Human Papilloma Virus (HPV) Testing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2021 & 2033
8.3. Human Papilloma Virus (HPV) Testing Market by Region: Key Takeaways
8.4. North America
8.4.1. U.S.
8.4.1.1. Key Country Dynamics
8.4.1.2. Regulatory Framework/ Reimbursement Structure
8.4.1.3. Competitive Scenario
8.4.1.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. Canada
8.4.2.1. Key Country Dynamics
8.4.2.2. Regulatory Framework/ Reimbursement Structure
8.4.2.3. Competitive Scenario
8.4.2.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Mexico
8.4.3.1. Key Country Dynamics
8.4.3.2. Regulatory Framework/ Reimbursement Structure
8.4.3.3. Competitive Scenario
8.4.3.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Germany
8.5.1.1. Key Country Dynamics
8.5.1.2. Regulatory Framework/ Reimbursement Structure
8.5.1.3. Competitive Scenario
8.5.1.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory Framework/ Reimbursement Structure
8.5.2.3. Competitive Scenario
8.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. France
8.5.3.1. Key Country Dynamics
8.5.3.2. Regulatory Framework/ Reimbursement Structure
8.5.3.3. Competitive Scenario
8.5.3.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. Italy
8.5.4.1. Key Country Dynamics
8.5.4.2. Regulatory Framework/ Reimbursement Structure
8.5.4.3. Competitive Scenario
8.5.4.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Spain
8.5.5.1. Key Country Dynamics
8.5.5.2. Regulatory Framework/ Reimbursement Structure
8.5.5.3. Competitive Scenario
8.5.5.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Denmark
8.5.6.1. Key Country Dynamics
8.5.6.2. Regulatory Framework/ Reimbursement Structure
8.5.6.3. Competitive Scenario
8.5.6.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Sweden
8.5.7.1. Key Country Dynamics
8.5.7.2. Regulatory Framework/ Reimbursement Structure
8.5.7.3. Competitive Scenario
8.5.7.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Norway
8.5.8.1. Key Country Dynamics
8.5.8.2. Regulatory Framework/ Reimbursement Structure
8.5.8.3. Competitive Scenario
8.5.8.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key Country Dynamics
8.6.1.2. Regulatory Framework/ Reimbursement Structure
8.6.1.3. Competitive Scenario
8.6.1.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. China
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory Framework/ Reimbursement Structure
8.6.2.3. Competitive Scenario
8.6.2.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. India
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory Framework/ Reimbursement Structure
8.6.3.3. Competitive Scenario
8.6.3.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. South Korea
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory Framework/ Reimbursement Structure
8.6.4.3. Competitive Scenario
8.6.4.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory Framework/ Reimbursement Structure
8.6.5.3. Competitive Scenario
8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. Thailand
8.6.6.1. Key Country Dynamics
8.6.6.2. Regulatory Framework/ Reimbursement Structure
8.6.6.3. Competitive Scenario
8.6.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Framework/ Reimbursement Structure
8.7.2.3. Competitive Scenario
8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Framework/ Reimbursement Structure
8.7.3.3. Competitive Scenario
8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Framework/ Reimbursement Structure
8.8.2.3. Competitive Scenario
8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Framework/ Reimbursement Structure
8.8.3.3. Competitive Scenario
8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Framework/ Reimbursement Structure
8.8.4.3. Competitive Scenario
8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Framework/ Reimbursement Structure
8.8.5.3. Competitive Scenario
8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/ Competition Categorization
9.3. Vendor Landscape
9.3.1. Key Company Heat Map Analysis, 2024
9.4. Company Profiles
9.4.1. Abbott
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Product Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. Biomedical Diagnostics
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. Product Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. bioMerieux
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. Product Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Bio-Rad Laboratories, Inc.
9.4.4.1. Company Overview
9.4.4.2. Financial Performance
9.4.4.3. Product Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Fujirebio
9.4.5.1. Company Overview
9.4.5.2. Financial Performance
9.4.5.3. Product Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. Oncolab
9.4.6.1. Company Overview
9.4.6.2. Financial Performance
9.4.6.3. Product Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. Hologic, Inc.
9.4.7.1. Company Overview
9.4.7.2. Financial Performance
9.4.7.3. Product Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Qiagen
9.4.8.1. Company Overview
9.4.8.2. Financial Performance
9.4.8.3. Product Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. F. Hoffmann-La Roche Ltd
9.4.9.1. Company Overview
9.4.9.2. Financial Performance
9.4.9.3. Product Benchmarking
9.4.9.4. Strategic Initiatives
9.4.10. Siemens Healthineers AG
9.4.10.1. Company Overview
9.4.10.2. Financial Performance
9.4.10.3. Product Benchmarking
9.4.10.4. Strategic Initiatives
°ü·ÃÀÚ·á